MedTrace Logo

The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)

NCT05208229 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2025-04-01

No results posted yet for this study

Summary

The role of WB-MRI in the evaluation of prostate cancer patients treated with Lu-PSMA

Conditions

  • Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions

DIAGNOSTIC_TEST

WB-MRI

Baseline CT scan (minimum thorax/abdomen/pelvis) and WB-MRI evaluations will be collected: as per clinical practice and Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol, the assessments must not be performed more than 12 weeks prior to study entry and baseline WB-MRI should be performed within 2 weeks from CT scan; CT and WB-MRI will be done at the end of Lutetium 177 PSMA (177Lu-PSMA) therapy and during post-treatment follow-up

Sponsors & Collaborators

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

    lead OTHER

Principal Investigators

  • Giovanni Paganelli, MD · IRST IRCCS

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-03-08
Completion
2022-03-08

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05208229 on ClinicalTrials.gov